Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2007 2
2008 1
2009 2
2010 3
2011 4
2012 5
2013 3
2014 2
2015 1
2016 2
2017 2
2020 1
2021 3
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.
Bissonnette R, Gottlieb AB, Langley RG, Leonardi CL, Papp KA, Pariser DM, Uy J, Lafferty KP, Langholff W, Fakharzadeh S, Berlin JA, Brouwer ES, Greenspan AJ, Strober BE. Bissonnette R, et al. Among authors: uy j. Drug Saf. 2021 Jun;44(6):699-709. doi: 10.1007/s40264-021-01065-z. Epub 2021 Jun 2. Drug Saf. 2021. PMID: 34075572 Free PMC article. Review.
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF. Walsh JA, et al. Among authors: uy j. Dermatol Ther (Heidelb). 2022 Jan;12(1):97-119. doi: 10.1007/s13555-021-00637-2. Epub 2021 Nov 25. Dermatol Ther (Heidelb). 2022. PMID: 34822121 Free PMC article.
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Armstrong AW, et al. Among authors: uy jp. Dermatol Ther (Heidelb). 2023 Feb;13(2):629-640. doi: 10.1007/s13555-022-00879-8. Epub 2022 Dec 31. Dermatol Ther (Heidelb). 2023. PMID: 36585606 Free PMC article.
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Armstrong AW, et al. Among authors: uy jp. Dermatol Ther (Heidelb). 2023 Feb;13(2):487-504. doi: 10.1007/s13555-022-00865-0. Epub 2022 Dec 9. Dermatol Ther (Heidelb). 2023. PMID: 36484917 Free PMC article.
31 results